Pretax income is the income that a company earns before paying income taxes. Lipella Pharmaceuticals's pretax income for the
three
months ended in Sep. 2024 was $-1.45 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.26 Mil.
Lipella Pharmaceuticals's pretax margin was -1,806.25%.
During the past 4 years, Lipella Pharmaceuticals's highest Pretax Margin was -6.44%. The lowest was -2121.39%. And the median was -873.26%.
Lipella Pharmaceuticals Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lipella Pharmaceuticals's Pre-Tax Income
For the Biotechnology subindustry, Lipella Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipella Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Lipella Pharmaceuticals's Pre-Tax Income falls into.
Lipella Pharmaceuticals Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Lipella Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipella Pharmaceuticals (NAS:LIPO) Pre-Tax Income Explanation
Lipella Pharmaceuticals's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
During the past 4 years, Lipella Pharmaceuticals's highest Pretax Margin was -6.44%. The lowest was -2121.39%. And the median was -873.26%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipella Pharmaceuticals Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Lipella Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIPO has been successfully added to your 